Login / Signup

Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.

Meera MohanSiegfried JanzRuta BrazauskasMichael B DwinellBi Qing TengGrant YunJing DongMarcelo C PasquiniSergio A GiraltHeather J LandauEdward StadtmauerAmrita KrishnanAnita D Souza
Published in: Bone marrow transplantation (2023)
Keyphrases
  • multiple myeloma
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • cell therapy
  • stem cells
  • stem cell transplantation
  • mesenchymal stem cells